Pharmaceutical & Life Sciences News

Mylan Wins Appeal Over Patent on Bausch Health’s Relistor

April 8, 2020, 4:18 PM

Trial court erred in rejecting Mylan’s invalidity argument on formulation patent for constipation treatment Relistor, U.S. Court of Appeals for the Federal Circuit ruled.

  • Salix, Bausch Health’s Valeant had sued Mylan to prevent it from selling generic until patent expires in April 2024
  • Case was remanded to trial court in New Jersey for further proceedings
  • Patent expires in April 2024: FDA Orange Book
  • Docket link

To contact the reporter on this story:
Susan Decker in Washington at sdecker1@bloomberg.net

To contact the editors responsible for this story:
Jon Morgan at jmorgan97@bloomberg.net

Vivek Shankar

© 2020 Bloomberg L.P. All rights...

To read the full article log in. To learn more about a subscription click here.